Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older

Clinical and Experimental Allergy

Volumn 31, Issue 6, 2001, Pages 845-854

  Williams, B ^a   Noonan, G ^a   Reiss, T F ^a   Knorr, B ^a   Guerra, J ^b   White, R ^c   Matz, J ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Social Security General Hospital   (Guatemala)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Asthma and Allergy Center   (United States)

Author keywords

Asthma; Beclomethasone; Cysteinyl leukotrienes; Inhaled corticosteroids; Montelukast; Tolerance; Treatment adherence

Indexed keywords

BECLOMETASONE; MONTELUKAST; RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASTHMA; CHILD; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TACHYPHYLAXIS; TIME;

ACETATES; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; CHILD; CHRONIC DISEASE; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOCYTE COUNT; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUINOLINES; TIME;

EID: 0035726032     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01085.x     Document Type: Article

References (29)

1. Comparison of patients' compliance with prescribed oral and inhaled asthma medications
2. Compliance in asthma
3. Adherence with twice-daily dosing of inhaled steroids. Socio-economic and health-belief differences
4. Relative safety and efficacy of inhaled corticosteroids
5. Effect of treatment with zileuton, a 5-1ipoxygenase inhibitor, in patients with asthma. A randomized controlled trial
6. The effect of inhibition of 5-1ipoxygenase by zileuton in mild-to-moderate asthma
7. 4) receptor antagonist, in patients with chronic asthma
8. 4 receptor antagonist, in subjects with bronchial asthma
9. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study with pranlukast, a novel leukotriene receptor antagonist
10. The role of leukotrienes in asthma and allergic rhinitis
11. Treatment of asthma with drugs modifying the leukotriene pathway
12. Leukotriene Ed and granulocytic infiltration into asthmatic airways
13. Leukotrienes are potent constrictors of human bronchi
14. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene DA receptor antagonist
15. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotrienereceptor antagonist
16. Montelukast, a potent leukotriene receptor antagonist, causes dose related improvements in chronic asthma
17. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, dodhle-blind trial
18. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, doubleblind trial
19. Acute and chronic effects of a 5-1ipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial
20. Leukotriene-receptor antagonists
21. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial
22. Measurement characteristics of two asthma symptom diary scales for use in clinical trials
23. Measuring the quality of life in children with asthma
24. Montehikast: The clinical safety profile
25. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
26. Antileukotriene drugs in the management of asthma